RAMIC: Design of a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of ramipril in patients with COVID-19

BACKGROUND AND AIMS: Retrospective studies have shown that angiotensin-converting-enzyme (ACE) inhibitors are associated with a reduced risk of complications and mortality in persons with novel coronavirus disease 2019 (COVID-19). Thus, we aimed to examine the efficacy of ramipril, an ACE-inhibitor,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ajmera, Veeral, Thompson, Wesley K., Smith, Davey M., Malhotra, Atul, Mehta, Ravindra L., Tolia, Vaishal, Yin, Jeffrey, Sriram, Krishna, Insel, Paul A., Collier, Summer, Richards, Lisa, Loomba, Rohit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899027/
https://www.ncbi.nlm.nih.gov/pubmed/33631357
http://dx.doi.org/10.1016/j.cct.2021.106330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899027/
https://www.ncbi.nlm.nih.gov/pubmed/33631357
http://dx.doi.org/10.1016/j.cct.2021.106330

Ejemplares similares